Home » Stocks » Gamida Cell

Gamida Cell Ltd. (GMDA)

Stock Price: $5.62 USD -0.04 (-0.71%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 278.03M
Revenue (ttm) n/a
Net Income (ttm) -34.35M
Shares Out 49.47M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $5.62
Previous Close $5.66
Change ($) -0.04
Change (%) -0.71%
Day's Open 5.69
Day's Range 5.51 - 5.74
Day's Volume 122,512
52-Week Range 2.60 - 7.70

More Stats

Market Cap 278.03M
Enterprise Value 224.50M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.47M
Float 27.24M
EPS (basic) -1.17
EPS (diluted) -1.87
FCF / Share -1.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 198,073
Short Ratio 1.44
Short % of Float 0.73%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.76
Revenue n/a
Operating Income -48.25M
Net Income -34.35M
Free Cash Flow -40.99M
Net Cash 53.53M
Net Cash / Share 1.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -38.63%
ROE -106.12%
ROIC -174.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(181.67% upside)
Current: $5.62
Target: 15.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-48.25-33.64-19.49-23.71
Net Income-34.35-52.93-19.01-22.67
Shares Outstanding24.935.030.690.69
Earnings Per Share-1.69-10.53-27.56-32.86
Operating Cash Flow-37.93-26.43-16.55-12.59
Capital Expenditures-3.06-1.65-0.40-0.28
Free Cash Flow-40.99-28.07-16.95-12.87
Cash & Equivalents55.4060.6941.0818.06
Total Debt1.87---
Net Cash / Debt53.5360.6941.0818.06
Book Value34.9824.6922.9610.96
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gamida Cell Ltd.
Country Israel
Employees 79
CEO Julian Adams

Stock Information

Ticker Symbol GMDA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GMDA
IPO Date October 26, 2018


Gamida Cell, a clinical stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.